Full Press Release Details
ROCKVILLE, Md.,May 7, 2026/PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.
Oral Presentations:The oral presentations include an overview of recent advancements in production titer and product quality achieved throughREGENXBIO's NAVXpress® manufacturing platform and an encore presentation oftoplinepivotal data from RGX-202, the company's next generation gene therapy program forDuchennemuscular dystrophy.
Title:Advancing AAV manufacturability toolbox for early programs and beyondPresenter:Metewo Selase Kosi Enuameh,Ph.D., Associate Director, Vector Core atREGENXBIOPresentation:266Session:AAVCritical Quality AttributesDate/Time:Thursday, May 14, 8:45 – 9:00am ETLocation:MCECRoom 204AB (Level 2)
Title:RGX-202: Investigational gene therapy for Duchenne Muscular DystrophyPresenter:Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's HospitalPresentation:506Session:In vivo clinical trials in eye and muscle disordersDate/Time:Friday, May 15, 4:30 – 4:45pm ETLocation:MCECRoom 210ABC (Level 2)
Poster Presentations:These presentations demonstrateREGENXBIO'scontinued leadership in the discovery and advancement of next-generation gene therapies for rare and retinal diseases, and highlight the company's uniquecapsidengineering and translational capabilities.
Title:NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered in the suprachoroidal space, demonstrates superior on-target activity compared to AAV8Poster:1031Presenter:BrendanLilley,Ph.D., Director of Ophthalmology Research,REGENXBIOLocation:MCECExhibit and Poster Hall (Halls B2-C, Exhibit level)Date/Time:Tuesday, May 12, 5:00 – 6:30pm ET
Title:Examination of Route-Dependent Ocular Transduction in Rodent Models by the Novel AAV Capsid NVG82Poster:3031Presenter:Huzzatul Mursalin,Ph.D., Scientist II, Gene Therapy Research,REGENXBIOLocation:MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level)Date/Time:Thursday, May 14, 5:00 – 6:30pm ET
Title:Development of an engineered hybrid AAV with reduced liver and DRG transduction and high productivityPoster:3030Presenter:SamanthaYost,Ph.D., Senior Scientist, Gene Therapy Research,REGENXBIOLocation:MCECExhibit and Poster Hall (Hall B2-C, Exhibit level)Date/Time:Thursday, May 14, 5:00 – 6:30pm ET
Title:Single-nuclei transcriptomic analysis of skeletal muscle mRNA in mdx mice treated with RGX-202, an AAV vector encoding micro-dystrophinPoster:3499Presenter:Justin Glenn, Ph.D., Principal Scientist, Gene Therapy Research, REGENXBIOLocation:MCEC Exhibit and Poster Hall (Hall B2-C, Exhibit level)Date/Time:Thursday, May 14, 5:00 – 6:30pm ET
All presentations will be available on the Publications page of REGENXBIO's website,www.regenxbio.com.
ABOUT REGENXBIO Inc.REGENXBIOis a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009,REGENXBIOhas pioneered the field ofAAVgene therapy.REGENXBIOis advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment ofDuchenne;clemidsogene lanparvovec(RGX-121) for the treatment ofMPSII and RGX-111 for the treatment ofMPSI, both in partnership withNippon Shinyaku; andsurabgene lomparvovec(ABBV-RGX-314) for the treatment of wetAMDand diabetic retinopathy, in collaboration withAbbVie. Thousands of patients have been treated withREGENXBIO's AAVplatform, including those receivingNovartis'ZOLGENSMA®.REGENXBIO'sinvestigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visitWWW.REGENXBIO.COM.
Contacts:
Dana CormackCorporate Communications[email protected]
Investors:George E.MacDougallInvestor Relations[email protected]
SOURCE REGENXBIO Inc.